-+ 0.00%
-+ 0.00%
-+ 0.00%

Foghorn Therapeutics cuts workforce about 40% in reorganization to extend cash runway into H2 2029

PUBT·10/01/2026 11:05:34
Foghorn Therapeutics cuts workforce about 40% in reorganization to extend cash runway into H2 2029
  • Foghorn launched a corporate reorganization to refocus on wholly owned programs following the decision to stop advancing FHD-909.
  • Workforce to shrink about 40% as operating structure is realigned to prioritize proprietary pipeline development.
  • Cash runway expected to extend into the second half of 2029 under the new plan.
  • Collaboration with Lilly to end, with no further work planned on FHD-909 or the selective SMARCA2 degrader program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foghorn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837518) on October 01, 2026, and is solely responsible for the information contained therein.